KDM3A drives NSCLC proliferation and metastasis via H3K9 demethylation, EMT activation and MMP-9 upregulation

Area of Science:

• Epigenetics
• Molecular Oncology
• Cancer Biology

Background:

• Histone methylation is key in lung cancer development.
• The specific role of lysine-specific demethylase 3A (KDM3A) in non-small cell lung cancer (NSCLC) is not well understood.
• Investigating KDM3A's function is crucial for understanding NSCLC pathogenesis.

Purpose of the Study:

• To elucidate the role of KDM3A in NSCLC progression.
• To investigate the molecular mechanisms by which KDM3A influences NSCLC cell behavior.
• To assess the therapeutic potential of targeting KDM3A in NSCLC.

Main Methods:

• Established NSCLC cell models with KDM3A overexpression and knockdown.
• Performed in vitro assays (proliferation, migration, invasion) and in vivo xenograft studies.
• Analyzed histone methylation (H3K9me2), epithelial-mesenchymal transition (EMT) markers, MMP-9, STAT3 pathway, and FOXP3 expression.
• Conducted clinical correlation analyses in NSCLC tissues.

Main Results:

• KDM3A depletion increased H3K9me2, suppressed proliferation, and impaired migration/invasion by attenuating EMT and MMP-9 expression.
• KDM3A overexpression reduced H3K9me2, promoted EMT, and enhanced metastasis via VIM and MMP-9 upregulation.
• KDM3A activated the p-STAT3 pathway, downregulating E-cadherin and promoting metastasis.
• KDM3A knockdown inhibited tumor growth in vivo.
• Elevated KDM3A in metastatic NSCLC correlated negatively with H3K9me2 and positively with FOXP3.

Conclusions:

• KDM3A acts as an epigenetic driver in NSCLC progression.
• KDM3A promotes NSCLC metastasis by regulating H3K9me2-dependent EMT and related pathways.
• KDM3A represents a promising therapeutic target for NSCLC treatment.